title: Constitutive transactivation by the thyroid hormone receptor and a novel pattern of activity of its oncogenic homolog v-ErbA in Xenopus oocytes.
abstract: In Xenopus oocytes, the rat thyroid hormone receptor alpha (rTR alpha), but not its oncogenic homolog v-ErbA, constitutively activated thyroid hormone (T3)-responsive reporter genes at four positive thyroid hormone-responsive elements (TREs). At a subset of the positive TREs tested, the addition of T3 resulted in a further enhancement of reporter gene activation. In contrast, both rTR alpha and v-ErbA functioned as constitutive activators when bound to the clone 122 TREs, which are induced by unliganded TR in mammalian cells. Therefore, the responses of the ligand-independent activation domains of TR and v-ErbA to cell-specific and TRE-mediated induction are not equivalent. Coexpression of the human retinoid X receptor alpha (hRXR alpha) enhanced both ligand-dependent and ligand-independent activation functions of rTR alpha and human TR beta (hTR beta) at a palindromic TRE (TREp). An endogenous TR activity mediated T3 induction of TREp, while being repressed by an in vitro-generated dominant negative mutant of TR. T3-mediated gene activation, by exogenous or endogenous TR, was repressed by v-ErbA at three positive TREs, but not at the TRE from the third intron of the rat GH gene (rGH3 TRE). Interestingly, preinjection of nuclear protein extract from anterior pituitary cells converted v-ErbA into a constitutive activator at rGH3 TRE. The pituitary-specific factor Pit-1/GHF-1 or hRXR alpha did not induce activation by v-ErbA at rGH3 TRE, suggesting that the dominant negative phenotype of v-ErbA can be abolished by direct or indirect interactions with other nuclear factors.
authors.affiliation: Department of Zoology, University of Canterbury, Christchurch, New Zealand.
authors.forename: S B
authors.initials: SB
authors.lastname: Nagl
authors.forename: C C
authors.initials: CC
authors.lastname: Nelson
authors.forename: P J
authors.initials: PJ
authors.lastname: Romaniuk
authors.forename: L A
authors.initials: LA
authors.lastname: Allison
mesh_terms: D000818:Animals; D001483:Base Sequence; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D017930:Genes, Reporter; D006801:Humans; D008024:Ligands; D008845:Microinjections; D008969:Molecular Sequence Data; D018774:Oncogene Proteins v-erbA / Q000502:physiology*; D009865:Oocytes; D009928:Organ Specificity; D010903:Pituitary Gland, Anterior / Q000378:metabolism; D051381:Rats; D018168:Receptors, Retinoic Acid / Q000235:genetics / Q000502:physiology; D011988:Receptors, Thyroid Hormone / Q000502:physiology*; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D012045:Regulatory Sequences, Nucleic Acid; D000072482:Retinoic Acid Receptor alpha; D012756:Sheep; D015533:Transcriptional Activation; D014284:Triiodothyronine / Q000378:metabolism / Q000494:pharmacology; D014982:Xenopus laevis
chemical_list: D008024:Ligands; D018774:Oncogene Proteins v-erbA; C000607071:RARA protein, human; C000607073:Rara protein, rat; D018168:Receptors, Retinoic Acid; D011988:Receptors, Thyroid Hormone; D011993:Recombinant Fusion Proteins; D000072482:Retinoic Acid Receptor alpha; D014284:Triiodothyronine